
Keywords: YF; yellow fever; YEL-AVD; yellow fever vaccine-associated viscerotropic disease; RR; reporting rates; RRR; reporting rate ratios; AVD; viscerotropic disease; AEFI; adverse events following immunization; serious AEFI; serious adverse events following immu